Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8
million annually. Mtb RNA polymerase (RNAP) is the target of the first-line antituberculosis …

Drug-resistant bacterial pathogens pose an urgent public-health crisis. Here, we report the
discovery, from microbial-extract screening, of a nucleoside-analog inhibitor that inhibits …

Objectives Currently, only a few antibiotics are available to treat methicillin-resistant
Staphylococcus aureus (MRSA). One alternative approach includes adjuvants to antibiotic …

Staphylococcus aureus (S. aureus) is the leading cause of a broad range of human
infections and associated with food poisoning worldwide. Nisin can be considered as a …

In recent years using nanoparticle has been increased to resolve microbial resistance. It has
been shown that nanomaterial such as metallic nanoparticles is the most effective in …

Combinatory therapies have been commonly applied in the clinical setting to tackle multi-
drug resistant bacterial infections and these have frequently proven to be effective …

Antibiotic-resistant infections kill approximately 23,000 people and cost $20,000,000,000
each year in the United States alone despite the widespread use of small-molecule …

Candida albicans is a major cause of fungal diseases in humans, and its resistance to
available drugs is of concern. In an attempt to identify novel antifungal agents, we initiated a …

The polymicrobial nature of ventilator-associated pneumonia (VAP) is now evident, with
mixed bacterial-fungal biofilms colonizing the VAP endotracheal tube (ETT) surface. The …